Works by Thuresson, Marcus

Results: 56
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 9, p. 687, doi. 10.1016/j.clml.2023.05.004
    By:
    • Sonneveld, Pieter;
    • Richardson, Paul G.;
    • Ludwig, Heinz;
    • Dimopoulos, Meletios-Athanasios;
    • Schjesvold, Fredrik H.;
    • Hajek, Roman;
    • Abdulhaq, Haifaa;
    • Thuresson, Marcus;
    • Norin, Stefan;
    • Bakker, Nicolaas A.;
    • Mateos, Maria-Victoria
    Publication type:
    Article
    11

    OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S32, doi. 10.1016/S2152-2650(21)02124-8
    By:
    • Schjesvold, Fredrik;
    • Dimopoulos, Meletios-Athanasios;
    • Delimpasi, Sosana;
    • Robak, Pawef;
    • Coriu, Daniel;
    • Legiec, Wojciech;
    • Pour, Ludek;
    • Špicka, Ivan;
    • Masszi, Tamás;
    • Doronin, Vadim;
    • Minarik, Jiri;
    • Salogub, Galina;
    • Alexeeva, Yulia;
    • Lazzaro, Antonio;
    • Maisnar, Vladimir;
    • Mikala, Gábor;
    • Moody, Victoria;
    • Thuresson, Marcus;
    • Byrne, Catriona;
    • Harmenberg, Johan
    Publication type:
    Article
    12

    MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S426, doi. 10.1016/S2152-2650(21)01952-2
    By:
    • Rodríguez-Otero, Paula;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Blade, Joan;
    • Cavo, Michele;
    • Leleu, Xavier;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agne;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Thuresson, Marcus;
    • Harmenberg, Johan;
    • Harlin, Olof;
    • Richardson, Paul G
    Publication type:
    Article
    13

    MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S427, doi. 10.1016/S2152-2650(21)01953-4
    By:
    • Richardson, Paul G;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Cavo, Michele;
    • Rodríguez-Otero, Paula;
    • Leleu, Xavier;
    • Norkin, Maxim;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agner;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Puig, Noemi;
    • Zamagni, Elena;
    • Thuresson, Marcus
    Publication type:
    Article
    14

    Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01575-5
    By:
    • Rodríguez-Otero, Paula;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Bladé, Joan;
    • Cavo, Michele;
    • Leleu, Xavier;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agne;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Thuresson, Marcus;
    • Harmenberg, Johan;
    • Harlin, Olof;
    • Richardson, Paul G
    Publication type:
    Article
    15

    Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01573-1
    By:
    • Richardson, Paul G.;
    • Mateos, María-Victoria;
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Cavo, Michele;
    • Rodríguez-Otero, Paula;
    • Leleu, Xavier;
    • Norkin, Maxim;
    • Nadeem, Omar;
    • Hiemenz, John W;
    • Hassoun, Hani;
    • Touzeau, Cyrille;
    • Alegre, Adrián;
    • Paner, Agner;
    • Maisel, Christopher;
    • Mazumder, Amitabha;
    • Raptis, Anastasios;
    • Puig, Noemí;
    • Zamagni, Elena;
    • Thuresson, Marcus
    Publication type:
    Article
    16

    Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.

    Published in:
    Cardiovascular Diabetology, 2019, v. 18, n. 1, p. N.PAG, doi. 10.1186/s12933-019-0942-x
    By:
    • Clegg, Lindsay E.;
    • Penland, Robert C.;
    • Bachina, Srinivas;
    • Boulton, David W.;
    • Thuresson, Marcus;
    • Heerspink, Hiddo J. L.;
    • Gustavson, Stephanie;
    • Sjöström, C. David;
    • Ruggles, James A.;
    • Hernandez, Adrian F.;
    • Buse, John B.;
    • Mentz, Robert J.;
    • Holman, Rury R.
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27

    Factors associated with lung cancer in COPD patients.

    Published in:
    International Journal of COPD, 2018, v. 13, p. 1833, doi. 10.2147/COPD.S162484
    By:
    • Sandelin, Martin;
    • Mindus, Stéphanie;
    • Thuresson, Marcus;
    • Lisspers, Karin;
    • Ställberg, Björn;
    • Johansson, Gunnar;
    • Larsson, Kjell;
    • Janson, Christer
    Publication type:
    Article
    28
    29
    30
    31

    Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.

    Published in:
    Cardiovascular Diabetology, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12933-021-01345-z
    By:
    • Khunti, Kamlesh;
    • Kosiborod, Mikhail;
    • Kim, Dae Jung;
    • Kohsaka, Shun;
    • Lam, Carolyn S. P.;
    • Goh, Su-Yen;
    • Chiang, Chern-En;
    • Shaw, Jonathan E.;
    • Cavender, Matthew A.;
    • Tangri, Navdeep;
    • Franch-Nadal, Josep;
    • Holl, Reinhard W.;
    • Jørgensen, Marit E.;
    • Norhammar, Anna;
    • Eriksson, Johan G.;
    • Zaccardi, Francesco;
    • Karasik, Avraham;
    • Magliano, Dianna J.;
    • Thuresson, Marcus;
    • Chen, Hungta
    Publication type:
    Article
    32
    33
    34
    35
    36

    Lower risk of cardiovascular events and death associated with initiation of sodium‐glucose cotransporter‐2 inhibitors versus sulphonylureas: Analysis from the CVD‐REAL 2 study.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2402, doi. 10.1111/dom.15092
    By:
    • Goh, Su‐Yen;
    • Kosiborod, Mikhail N.;
    • Lam, Carolyn S. P.;
    • Cavender, Matthew A.;
    • Kohsaka, Shun;
    • Norhammar, Anna;
    • Birkeland, Kåre I.;
    • Holl, Reinhard W.;
    • Mauricio, Dídac;
    • Tangri, Navdeep;
    • Shaw, Jonathan E.;
    • Thuresson, Marcus;
    • Fenici, Peter;
    • Kim, Dae Jung
    Publication type:
    Article
    37

    Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1277, doi. 10.1111/dom.14698
    By:
    • Norhammar, Anna;
    • Bodegard, Johan;
    • Eriksson, Jan W.;
    • Haller, Hermann;
    • Linssen, Gerard C. M.;
    • Banerjee, Amitava;
    • Karasik, Avraham;
    • Mamouris, Pavlos;
    • Tangri, Navdeep;
    • Taveira‐Gomes, Tiago;
    • Maggioni, Aldo P.;
    • Botana, Manuel;
    • Thuresson, Marcus;
    • Okami, Suguru;
    • Yajima, Toshitaka;
    • Kadowaki, Takashi;
    • Birkeland, Kåre I.
    Publication type:
    Article
    38

    Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1431, doi. 10.1111/dom.14356
    By:
    • Lam, Carolyn S. P.;
    • Karasik, Avraham;
    • Melzer‐Cohen, Cheli;
    • Cavender, Matthew A.;
    • Kohsaka, Shun;
    • Norhammar, Anna;
    • Thuresson, Marcus;
    • Chen, Hungta;
    • Wittbrodt, Eric;
    • Fenici, Peter;
    • Kosiborod, Mikhail
    Publication type:
    Article
    39
    40
    41

    Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 75, doi. 10.1111/dom.14189
    By:
    • Birkeland, Kåre I.;
    • Bodegard, Johan;
    • Banerjee, Amitava;
    • Kim, Dae Jung;
    • Norhammar, Anna;
    • Eriksson, Jan W.;
    • Thuresson, Marcus;
    • Okami, Suguru;
    • Ha, Kyoung Hwa;
    • Kossack, Nils;
    • Mamza, Jil Billy;
    • Zhang, Ruiqi;
    • Yajima, Toshitaka;
    • Komuro, Issei;
    • Kadowaki, Takashi
    Publication type:
    Article
    42
    43

    Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1607, doi. 10.1111/dom.14074
    By:
    • Birkeland, Kåre I.;
    • Bodegard, Johan;
    • Eriksson, Jan W.;
    • Norhammar, Anna;
    • Haller, Hermann;
    • Linssen, Gerard C.M.;
    • Banerjee, Amitava;
    • Thuresson, Marcus;
    • Okami, Suguru;
    • Garal‐Pantaler, Elena;
    • Overbeek, Jetty;
    • Mamza, Jil Billy;
    • Zhang, Ruiqi;
    • Yajima, Toshitaka;
    • Komuro, Issei;
    • Kadowaki, Takashi
    Publication type:
    Article
    44
    45
    46
    47
    48

    Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 8, p. 1983, doi. 10.1111/dom.13299
    By:
    • Kosiborod, Mikhail;
    • Birkeland, Kåre I.;
    • Cavender, Matthew A.;
    • Fu, Alex Z.;
    • Wilding, John P.;
    • Khunti, Kamlesh;
    • Holl, Reinhard W.;
    • Norhammar, Anna;
    • Jørgensen, Marit E.;
    • Wittbrodt, Eric T.;
    • Thuresson, Marcus;
    • Bodegård, Johan;
    • Hammar, Niklas;
    • Fenici, Peter;
    • the CVD‐REAL Investigators and Study Group
    Publication type:
    Article
    49

    Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 344, doi. 10.1111/dom.13077
    By:
    • Persson, Frederik;
    • Nyström, Thomas;
    • Jørgensen, Marit E.;
    • Carstensen, Bendix;
    • Gulseth, Hanne L.;
    • Thuresson, Marcus;
    • Fenici, Peter;
    • Nathanson, David;
    • Eriksson, Jan W.;
    • Norhammar, Anna;
    • Bodegard, Johan;
    • Birkeland, Kåre I.
    Publication type:
    Article
    50